LFCR vs BDX

For growth investors, Becton, Dickinson and Company (BDX) is the stronger pick with 8.

2% revenue growth year-over-year, versus 0. 5% for Lifecore Biomedical, Inc. (LFCR). Becton, Dickinson and Company (BDX) offers the better valuation at 26. 3x trailing P/E (12. 3x forward), making it the more compelling value choice. Analysts rate Lifecore Biomedical, Inc. (LFCR) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Becton, Dickinson and Company (BDX) delivered a total return of +16.

9%, compared to -61. 9% for Lifecore Biomedical, Inc. (LFCR). Over 10 years, the gap is even starker: BDX returned +80. 2% versus LFCR's -56. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Becton, Dickinson and Company (BDX) is the lower-risk stock at 0.

66β versus Lifecore Biomedical, Inc. 's 1. 39β — meaning LFCR is approximately 111% more volatile than BDX relative to the S&P 500. On balance sheet safety, Becton, Dickinson and Company (BDX) carries a lower debt/equity ratio of 76% versus 98% for Lifecore Biomedical, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Becton, Dickinson and Company (BDX) is pulling ahead at 8.

2% versus 0. 5% for Lifecore Biomedical, Inc. (LFCR). On earnings-per-share growth, the picture is similar: Becton, Dickinson and Company grew EPS -0. 5% year-over-year, compared to -484. 8% for Lifecore Biomedical, Inc.. Over a 3-year CAGR, LFCR leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Becton, Dickinson and Company (BDX) is the more profitable company, earning 7.

7% net margin versus -30. 0% for Lifecore Biomedical, Inc. — meaning it keeps 7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDX leads at 11. 8% versus -13. 4% for LFCR. At the gross margin level — before operating expenses — BDX leads at 45. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for LFCR: 25.

8% to $6. 00.

In this comparison, BDX (2.

7% yield) pays a dividend. LFCR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), 2. 7% yield). Both have compounded well over 10 years (BDX: +80. 2%, LFCR: -56. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

BDX pays a dividend while LFCR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.